• LAST PRICE
    41.1400
  • TODAY'S CHANGE (%)
    Trending Down-1.9800 (-4.5918%)
  • Bid / Lots
    39.3100/ 1
  • Ask / Lots
    42.7300/ 1
  • Open / Previous Close
    42.2300 / 43.1200
  • Day Range
    Low 40.2200
    High 42.9300
  • 52 Week Range
    Low 14.1900
    High 72.2900
  • Volume
    396,460
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 43.12
TimeVolumeAPGE
09:32 ET94242.17
09:34 ET34942.26
09:39 ET198442.7277
09:41 ET10042.38
09:43 ET37542.645
09:45 ET30042.64
09:48 ET10042.63
09:50 ET84642.59
09:52 ET50042.67
09:54 ET40042.525
10:01 ET20042.26
10:03 ET20042.16
10:08 ET190042.205
10:10 ET50042.08
10:12 ET10042.08
10:14 ET60042
10:15 ET10041.97
10:17 ET60042.08
10:19 ET22042.045
10:21 ET10042.06
10:24 ET140041.96
10:28 ET50042.09
10:32 ET100042.22
10:33 ET50042.19
10:37 ET25042.165
10:39 ET250742.205
10:42 ET30042.09
10:44 ET70041.92
10:46 ET139841.88
10:48 ET210041.77
10:50 ET390041.79
10:51 ET140041.62
10:53 ET20041.86
10:55 ET10041.74
10:57 ET20041.92
11:00 ET50042.015
11:04 ET80041.94
11:06 ET20041.77
11:08 ET10041.73
11:13 ET10041.98
11:20 ET20041.8125
11:24 ET10041.92
11:27 ET10041.86
11:29 ET80041.91
11:31 ET20041.99
11:36 ET21241.88
11:42 ET80041.57
11:51 ET20041.62
11:54 ET20041.59
11:56 ET10041.62
11:58 ET160041.4
12:00 ET65341.41
12:02 ET160041.325
12:03 ET30041.43
12:05 ET36641.41
12:07 ET40041.465
12:09 ET40041.62
12:12 ET40041.66
12:18 ET20041.74
12:20 ET10041.745
12:21 ET20041.85
12:25 ET104441.666
12:27 ET30041.53
12:30 ET10041.51
12:34 ET45741.4469
12:36 ET40041.56
12:38 ET20041.57
12:41 ET100841.61
12:43 ET40041.64
12:48 ET70041.435
12:57 ET10341.408
01:08 ET20041.58
01:10 ET20041.65
01:12 ET110041.96
01:14 ET20042
01:21 ET110041.895
01:24 ET60041.81
01:32 ET40041.73
01:42 ET50041.63
01:44 ET10041.57
01:48 ET120041.635
01:50 ET50041.42
01:51 ET11841.42
01:53 ET423941.395
01:55 ET11541.35
01:57 ET70041.22
02:02 ET70041.11
02:06 ET289141.255
02:13 ET20041.27
02:15 ET10041.15
02:18 ET107241.1
02:20 ET10041.12
02:22 ET100041.125
02:26 ET134840.98
02:27 ET40040.93
02:31 ET20040.91
02:38 ET353740.91
02:40 ET50040.89
02:42 ET10040.82
02:45 ET160040.775
02:47 ET20040.67
02:49 ET50040.725
02:51 ET373440.59
02:54 ET10040.6
02:56 ET399840.55
02:58 ET173040.46
03:00 ET2347240.54
03:02 ET258340.52
03:03 ET125640.55
03:05 ET75040.4
03:07 ET30040.4
03:09 ET200740.5
03:12 ET459040.5
03:14 ET262240.44
03:20 ET20040.505
03:21 ET20040.5
03:23 ET55040.515
03:25 ET30040.45
03:27 ET10040.43
03:30 ET10040.515
03:32 ET20140.515
03:34 ET772040.55
03:36 ET284440.4
03:38 ET127840.22
03:39 ET284440.5
03:41 ET470640.75
03:43 ET141140.75
03:45 ET2558041.1
03:48 ET272841.04
03:50 ET219941.22
03:52 ET519641.19
03:54 ET300040.84
03:56 ET602740.94
03:57 ET789641
03:59 ET1484341.14
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesAPGE
Apogee Therapeutics Inc
2.4B
-20.1x
---
United StatesCGON
CG Oncology Inc
2.3B
-30.8x
---
United StatesIOVA
Iovance Biotherapeutics Inc
2.3B
-4.5x
---
United StatesCLDX
Celldex Therapeutics Inc
2.3B
-12.2x
---
United StatesMLTX
MoonLake Immunotherapeutics
2.6B
-55.2x
---
United StatesNTLA
Intellia Therapeutics Inc
2.4B
-4.7x
---
As of 2024-06-15

Company Information

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.

Contact Information

Headquarters
221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
Phone
650-394-5230
Fax
302-655-5049

Executives

Independent Chairman of the Board
Mark McKenna
Chief Executive Officer, Director
Michael Henderson
Chief Financial Officer
Jane Henderson
Chief Medical Officer
Carl Dambkowski
Independent Director
Lisa Bollinger

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$2.4B
Revenue (TTM)
$0.00
Shares Outstanding
58.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.04
Book Value
$7.86
P/E Ratio
-20.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.